MTOR and ovarian carcinoma: Finally, there also appears to be cross-talk between DYRK1B and the mammalian target of rapamycin (mTOR) pathway, with DYRK1B expression upregulated upon mTOR inhibition [109] and mTOR/AKT activation induced by DYRK1B within the Hh signaling pathway in pancreatic and ovarian cancer cells [115].